Efforts in research quality have led to a diffusion of publication guidelines for high-quality reporting of medical evidence with the aim to instill transparency to its evaluation. The maturity of this process has led to a second stage in which a surplus of scales measuring methodological quality is in place. However, there is no clear consensus as to which of these guidelines should be recommended for usage and how to integrate the methodological quality information into the evidence synthesis process. One major challenge that these scales poses is the fact that slight modifications performed to them in order to adapt to a specific research and/ or management question requires revalidation of the scale's properties, a clearly impractical endeavor. This article proposes a potential alternative to this challenge through the formulation of a framework in which quality elements are divided into tiers. This layering aims at separating quality constructs that should be uniformly present across all studies and thus could be validated from constructs that are question-specific and less likely to undergo a formal validation process. An example of this framework applied to the urological literature is presented.
So far, the evidence-based medicine paradigm has given more weight to internal validity-most likely due to its subsequent influence on external validity-and thus has proposed a hierarchy of study designs in ascending order of bias control. In this way, the appearance of three features which contribute in different ways to such bias control raises the strength of the design within the hierarchy. These features are, a prospective follow-up (over retrospective data collection); use of randomization (experimentation versus observation); and finally replication of the evidence (systematic reviews or multiple centers/ practices over single-center cohorts). The preponderance of this view is not without debate especially in settings where some of the more desirable features are difficult to implement. Walach et al. [2006] proposed an alternate view to the strength of the evidence. This view suggests a circular rather than a pyramidal chain of evidence, where the different study designs play a determined and complementary role trying to achieve a better balance between internal and external validity. In their basis for this view, Walach et al. put into perspective interesting aspects of the pyramidal approach that may explain some of the objections it confronts. One aspect is the fact that the pyramidal view was developed to assess the evidence of the effect of pharmacological therapy. This view may work well for questions of efficacy but it may be inadequate for more complex interventions and/or settings as those observed in surgery and complementary and alternative medicine. We could say that this view of enhancing the information provided by differing experimental designs is not new, as proposed by Susan Horn [2006] who suggested the feedback between randomized controlled trials and observational studies for a better assessment of outcomes.
Thus the inherent properties of the study design drive the quality of the resulting evidence. Even for clinical trials, there is empirical evidence that violations to design and conduct elements such as concealment of allocation and blinding may lead to overestimation of treatment effects [Schulz et al. 1995] , which may be increased in cases of less objective outcome measures [Wood et al. 2008] . The size of the errors and preponderance of design elements influencing those errors may well vary across fields, interventions, and research questions [Balk et al. 2002] , and thus warrant further investigation. Armijo et al. [2008] differentiate two facets of quality in experimentation, which frequently are taken interchangeably. These are reporting and methodological quality. There has been an intensive process performed by working groups aimed at generating guidelines for reporting of the scientific evidence. These guidelines have the major goal of instilling transparency to the research process facilitating in this way the critical appraisal of the literature. Although the items contained in these guidelines may not necessarily measure dimensions of quality per se, they definitely allow identifying the presence of such elements.
Faces of quality: reporting quality
The first of these initiatives is the Consolidated Standards of Reporting Trials (CONSORT) statement . In its most recent version a series of 22 items describing study planning, design and execution, guide authors in the reporting of twoarm parallel randomized controlled trials. Given that most of the items considered reflect core domains of methodological quality, adaptations and extensions to the CONSORT statements have allowed the elaboration of guidelines for most study designs and types of interventions. Further information on these guidelines can be found at the CONSORT website (http://www. consort-statement.org/). Studies assessing the impact of these guidelines indicate that the use of the CONSORT statement improves the quality of reporting [Kane et al. 2007; Deveraux et al. 2002; Moher and Lepage, 2001] .
Faces of quality: methodological quality
In terms of methodological quality, only a few though comprehensive evaluations of scoring systems have been undertaken. These assessments highlight an important and often overlooked distinction between checklists of items and scales. Scales are deemed stronger in the information they provide because in their design one or more constructs of the concept being evaluated (in this case quality) are considered, a quantitative measure is given to these elements, and in addition they are usually subjected to a process of psychometric assessment (validity, responsiveness and reliability). Armijo et al. [2008] in the context of physical therapy trials, elaborated further in the issue of quality scales, their validity and their use. The authors noted that the wide range of scales is the product of extensions and/or modifications of existing scales in order to fit the requirements of a specific topic (i.e. to consider issues that are relevant in a particular field and/or scientific question), also they differ in the degree of importance that each author ascribes to the individual quality constructs [ Jü ni et al. 1999 ]. The addition or subtraction of just a single item from a scale, changes to the weighting system, or other modifications may alter the psychometric properties of the scale. This means that such properties need to be re-assessed. They also indicated that as any other process, assessment of methodological quality is susceptible to bias, and thus the authors question themselves about elements that should be deemed relevant. They highlighted five elements for which there is empirical evidence of their influence in the results. These are randomization, allocation concealment, blinding, statistical power, and intention-to-treat analysis (also core elements of the CONSORT statement). West et al. [2002] from the Evidence Based Practice Center at the University of North Carolina accomplished a daunting task of appraising the existing literature as of 2001 regarding the evaluation of checklists and scales for methodological quality and strength of evidence for four major study designs. After a priori planned literature selection and extraction process, they assessed approximately 121 systems related to the quality of systematic reviews, randomized controlled trials, observational and diagnostic accuracy studies. They found that 19 systems were rather comprehensive in evaluating methodological quality as per the criteria they deemed relevant, although they did not advocate anyone in particular. Notwithstanding, these criteria are very close to the items suggested by the CONSORT publication guidelines and are based on the constructs presented by Lohr and Carey [1999] as influential of quality. Moja et al. [2005] assessed the methodological quality among 854 systematic reviews performed by the Cochrane group and others appearing in paper-based journals. They found that currently there is no consensus on the ideal checklist and scale for assessing such methodological quality. They also found that despite the more frequent assessment of the methodological quality by the Cochrane group in their reviews compared to paper-based reviews, they failed similarly in the inclusion of such quality assessment into the interpretation of the results.
What is the status of evidence quality in urology?
Limitations in the quality of reporting are not exclusive of a particular medical field. However, it seems that the incorporation of CONSORT and derived guidelines by authors have been adopted more effortlessly in general medicine than in specialty fields [Mills et al. 2005] , even among those that endorse the statements. Scales et al. [2008a] conducted a review of the quality of reporting of randomized controlled trials within the urologic literature, including the statistical methods employed in them [Scales et al. 2008b] . The review was based on 152 articles published in 1996 and 2004 (before and after the CONSORT statement) in the Journal of Urology, Urology, European Urology and British Journal of Urology International. Based on the 22 items of the CONSORT statement, the average score went from 10.2 in 1996 to 12 in 2004. The specific statistical components evaluated were sample size calculation; identification of significance level, statistical tests, primary outcome, and intent-to-treat estimation; reporting of non-significant p-values, effect size, and its precision; handling of multiple tests. The authors found that although progress in the reporting and/or use of some of the items was observed between the two periods, there is still substantial room for improvement.
Consequences of the literature not adhering more closely to the proposed statements of quality reporting can be found in the guidelines preparation enterprise. The American Urologic Association has developed ten clinical practice guidelines for common urologic conditions (see www.auanet.org/conent/guidelines-and-qualitycare/clinical-guidelines.cfm). Consistently, the panels in charge of developing such guidelines have found limitations in the reporting of the literature, which in some cases have precluded the elaboration of a meta-analysis due to disparate outcome measures and/or populations (Clinical Guidelines for Premature Ejaculation), or restricted the Panel from making statements at stronger levels such as recommendations and standards (Clinical Guidelines for Female Stress Urinary Incontinence). The reporting limitations more commonly indicated by these panels across the varied set of conditions are as follows.
(1) Lack of standardized definitions for two major components, the patient population (characteristics and inclusion/exclusion criteria), and the outcome measure (the outcome itself and instruments to measure it).
(2) Lack of stratification of outcomes by known important factors such as disease stage, disease-specific factors (e.g., stone size, patient age groups) and interventions. The lack of stratification by interventions is the least observed limitation, but still few publications present it. (3) Time interval at which outcomes are measured and complete time interval of the study. (4) Uniform reporting of complications that could follow the NIH Common Toxicity Assessment system. This system describes the type and severity of complications. Also, it requires the indication of the number of patients experiencing each complication described. (5) Appropriate statistical reporting of characteristics and effect size (measures of central tendency and variability for continuous variables, and frequency distributions for categorical variables with cutoff meaningful for the condition in question).
It will enhance significantly the quality of urological research if these considerations are regularly incorporated, also if details of particular definitions and measures used are provided because despite the lack of standardization such details can aid in translating between the dissimilar reports.
Challenges in research quality in urology
In addition to the current limitations indicated above, urology as a surgical discipline, confronts additional challenges in the conduct of high quality research in terms of both the study design and conduct standpoints. Review of these challenges have been performed in the surgical context by McCulloch et al. [2002] and by the CONSORT group when extended the guidelines for reporting non-pharmacologic treatment trials [Boutron et al. 2008 ]. Among these challenges more notably are the surgeon and patient's state of equipoise, the feasibility of blinding and risks of blinding failure, the surgeon's level of expertise in general and learning curve for the specific procedure and/or its components, and the technical details of the procedure and the surgeon's particular modifications. Surgical expertise and particular technique present challenges to the standardization of treatment, compliance of care providers with the protocol, to reproducibility and generalizability of findings, and make these trials potentially susceptible to performance and differential expertise biases. Many if not all of these challenges require creative solutions.
To deal with surgeon's equipoise, for example, modifications to the customary randomized trial may be needed. Alternatives to this are expertisebased randomized controlled trials [Devereaux et al. 2005] , or non-randomized preference arms [McCulloch et al. 2002] , both of which could be encompassed within pragmatic trials in the surgical setting. In expertise-based trials randomization takes place at the surgeon level (like cluster randomized trials) and therefore the surgeons would perform the type of surgery in which they are skilled. This will in turn bring the complexities inherent to cluster trials such as cluster randomization, and increased sample size. If there is a lack of surgeons equivalently skilled in each of the procedures being evaluated the trial may be prone to a differential expertise bias. Also, these studies are prone to selection bias at the individual level [Puffer et al. 2003 ]. At the analysis stage, accounting for the clustered nature of the design has been frequently disregarded [Campbell et al. 2004 ]. Ideally, if just a few of the surgeons are skilled in all the procedures evaluated, then randomization could be done in two levels. Random allocation of patients to these multi-skilled surgeons could be performed and direct comparisons of such interventions could be done, and then increase in power could be achieved by including the outcomes from patients in whom randomization took place at the surgeon's level employing a network meta-analytic technique.
Regarding the learning curve, it has been suggested to not include surgeons until they have reached the plateau curve for a particular procedure [Lawrence, 1991] . We could also propose to develop analytical approaches where the learning experience could form part of the evaluation, for example using time-dependent covariates like in the analysis of time-to-event outcomes.
In this regard, tools for statistical quality control (e.g., control charts) could also prove useful in improving the quality of the information gathered in trials and studies of surgery.
In terms of blinding, alternatives such as sham procedures or blinding of participants to study hypothesis have been implemented [Boutron et al. 2008 ]. However, these strategies pose ethical conflicts in particular to the consent process, the equipoise principle, and the exposure to unnecessary burden.
Finally, it may be important to recognize that depending on the particular outcome measure and research question, randomized trials might not be the only suitable study design for evaluating efficacy of interventions as noted by Black [1996] , who summarized situations -dramatic effect sizes, rare events-in which observational studies provide sufficient evidence of efficacy beyond the potential detrimental effects of bias and confounding.
What next? . . . A three-tier quality score The greater acceptance and use of the quality reporting guidelines by editors and authors are paving the way to a second phase that is, the systematic evaluation of the quality of the evidence in itself. Similarly to the consensus reached on quality reporting and the consequent development of guidelines for the whole spectrum of study designs and interventions, it is necessary to achieve a consensus on the appropriate methodological quality scale or scales before further proliferation makes this a more challenging task.
The literature seems to indicate that the elaboration of a 'global' quality scale that would be applicable to all study designs and scientific questions although a desirable goal might be somewhat unrealistic. Still, there are certain elements crucial to all studies. A plausible venue is the elaboration of a three-tier scale. The goal would be to enable validation of elements that should be present uniformly in any research by grouping them in certain tiers leaving other elements that are specific to a given question for other tiers. The score from the study-specific tier, although undesirable, may not be validated. Initially, we could give one point for achievement of each of the quality constructs examined to generate the summary score of each tier. Further evaluation of the measurement properties of each tier (at least for the first two) may lead to a weighting system concordant to the relevance of each construct to the overall concept of quality.
The first tier would cover the core elements or quality domains (reporting of the majority is suggested in CONSORT, and outlined in Lohr and Carey [1999] ). The universality of these components will grant consistency to the tier's psychometric properties across designs and scientific questions, and therefore comparability across studies. We could use part of this first tier any of the existing scales that were found comprehensive in evaluating empirical and best practice constructs [West et al. 2002] . The second tier would cover elements specific to a particular study design (e.g. diagnostic accuracy studies) not covered by the first-tier scale and thus will have unaltered psychometric properties within that specific design. In the same way, comparability of the score will be across the particular design. The third tier would cover elements specific to the question being addressed and for which its psychometric properties most likely would change with slight alterations to the question. The properties of the third-tier score probably would require re-assessment for each scientific question and thus unlikely to be accomplished. It is important to highlight that the assessment of these methodological quality items in any published study will be strongly affected by the adherence to the reporting guidelines. Our choice of quality scale (for any of the tiers, validated or not) as well as how many tiers we consider will be dictated by the degree of comprehensiveness we would like to achieve and resource constraints. However, we should at least aim at using the firsttier scale to systematically evaluate the evidence.
How to build the tiers of such a scale? One approach would be to consider the ''ideal'' protocol we can formulate to answer the particular scientific question considering elements that contribute to both internal and external validity. Most likely this ideal study would need to be adapted to a more realistic scenario as dictated by ethical, logistic and/or financial constraints. This would become the 'reference' study against which we will be able to measure the quality of the studies reported in the literature for that particular scientific question. Considering current work the elements most likely to form part of the first-tier score together with their rationale and type of validity they would influence are outlined in Table 1 .
As previously indicated, the third-tier score is question and time-specific. The latter refers to the continuously changing nature of medical knowledge and evidence, and thus issues that may form part of the quality criteria for a specific question during a given period of time may become standard-thus part of eligibility criteria for the study-or obsolete in a future evaluation. Also, depending how the criteria are formulated, these could become the indicators of elements in the first-tier (e.g. specific items concerning eligibility criteria or sample description) rather than components of the third-tier.
In order to illustrate the generation of a third-tier score, the case of studies addressing resolution of incontinence after radical prostatectomy will be used. Some of the items indicated may well be part of the sample selection criteria (as dictated by the investigators) and thus would not be included in the quality score, or if the scale used is already validated then this particular component would not help in discriminating the quality across studies. The elements that would likely measure quality of research for the proposed question are outlined below. Issues 1-5 emphasize the definition and assessment of the outcome measure. The lack of consensus and standardization in the literature regarding continence assessment in the framework of radical prostatectomy [Glickman et al. 2009 ] stresses the need for considering these items. Issues 6-12 aim at assessing the presence and distribution of potential confounders regarding patient population, surgical technique, and natural history of the condition that could affect both internal and external validity of findings. Depending on the goals of a particular study, outcomes stratified by some of these confounders would be required.
(1) Explicit definition of continence (0 pads versus 0 pads þ security pads versus 1 pad). Table 1 . Elements to consider in a scale of choice for the first tier.
Criterion Rationale Validity
Assist in establishing causality -The author provides and/or there is a strong rationale for the intervention to produce the hypothesized effect.
-Represents the biological plausibility of the Bradford Hill model of causality in Epidemiology.
Both
-Prospective versus retrospective data collection.
-Represents the temporality item of the Bradford Hill model of causality. Facilitates the direction of action from cause to effect.
Internal
Assist in controlling selection bias -Concordance of eligibility criteria with the specific question(s) being addressed (e.g. age groups, baseline parameters, medical conditions, etc.).
-Determines the population of interest in whom it is believed the intervention will work.
Both -Explicit indication of subject sources.
-Measures representativity of the sample. Both -Appropriate statistical sample description.
-Measures adequacy and representativity of the sample. In the case of multiple samples, allows assessing the similarity of groups -empirically found to influence outcomes.
Both -Allocation to intervention (random versus non-random versus mixed).
-Allows handling and/or evaluating selection bias. Empirically demonstrated.
Assist in controlling measurement bias -Blinding of outcome assessor.
-Empirical evidence has shown its influence on outcomes in some scenarios, particularly for subjective outcomes.
Internal -Explicit definition of outcome measures.
-Determines whether study will be able to answer the proposed question, and allows comparability among similar studies.
Both
-Choice of effect size in agreement to current knowledge in the field.
-Determines the medical validity and usability of the intervention.
-Use of right instruments to measure the outcomes. If standards instruments/measurements have been developed in the field, are these the ones being used?
-Assesses whether the outcomes and findings are relevant to the study question, and obtained via valid/comparable methods.
-Description of the time/length for evaluation of outcome(s).
-Assesses whether enough time is allowed to observe the outcomes of interest.
Assist in controlling exposure, withdrawal and analytical biases -Blinding of the other study agents (i.e. subjects, investigators, caregivers).
-Empirical evidence has shown its influence in reducing bias in some scenarios.
Internal -Indication whether the findings reported correspond to the primary or to secondary aims of the study originally designed.
-Assesses potential data dredging and adequacy of overall design to answer the question.
Internal
-Adequate power to answer the question.
-Supported by statistical theory. Internal -Intent-to-treat analysis.
-There is empirical evidence of its influence. Internal -Use of appropriate statistical estimates, tests, and/or models with verification of their assumptions (includes control of confounders).
-Provides precision of estimates. Allows assessing whether the right analytical tools have been used given the characteristics of the data and the outcomes.
Internal -Handling of multiplicity in analysis (multiple tests, stratified and adjusted analyses).
-Controls for spurious findings. Internal -Explanation for missing data. This may refer to the amount of non-responses or to losses of follow-up in cross-sectional or longitudinal designs respectively.
-Impact on internal and external validity depends on the amount, nature, and type of variable with missing information.
Both -Adherence of subjects to the intervention.
-Non-adherence precludes the measurement of the intervention effect as well as its applicability/sustainability in real life.
Both
Setting -Indication of the location, period and setting where study was conducted.
-Allows finding potential sources of heterogeneity. External 
Implications for urology
The surgical nature of a considerable number of management strategies in urology and thus the need for performing research beyond the structure of the classical parallel randomized trial, as well as the seemingly context-dependent association of quality measures with effect estimates [Wood et al. 2008; Balk et al. 2002; Jü ni et al. 1999 ] suggest the following venues. We need to assess the association of validated tierone scales (i.e., current existing quality scales) in diverse designs and topics in urology. We could start with prevalent conditions, or those for which medical societies have already generated practice guidelines. We would need to select questions where heterogeneity is present in order to be able to observe a potential association with quality. We would need to assess the association of each item from the quality scales (starting with the empirical items for example) with the effect size observed, being careful about the type of study design used and the objectivity of the outcome measure. We would also need to assess the potential relation of the overall association structure among constructs with the individual effects observed. Could a distinctive pattern be inferred from these two analyses? This would help in determining what aspects of study design and conduct make a greater impact within urologic research, and therefore consistently considered. In a similar fashion, we could assess the role of items specific to questions outlined within third-tier invalidated scales, to determine which processes within a particular question influence outcome effects beyond the influence of more standard quality items. In the overall, these steps would aid in determining which scales would be more helpful and fair in evaluating the quality of research in the field, and would let us proceed with the next step of determining how to incorporate the quality into the estimates of evidence.
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